Top

Published in:

01-03-2011

What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salipingo-oophorectomy

Authors: Danielle Campfield Bonadies, Anne Moyer, Ellen T. Matloff

Published in: Familial Cancer | Issue 1/2011

Abstract

We retrospectively studied BRCA carriers with a history of prophylactic bilateral salingo-oophorectomy (PBSO) regarding: (1) their post-operative symptoms, (2) their recollection of pre-operative conversations with their health care providers regarding possible surgical side-effects and (3) what information they would have found helpful to have before surgery. Female BRCA carriers seen through the Yale Cancer Genetic Counseling Program who had PBSO were invited to participate in a questionnaire that assessed their recall of information they received pre-operatively compared with their post-operative knowledge and symptoms related to menopause, cognitive changes, loss of fertility, cancer risks, osteoporosis, heart disease, vasomotor symptoms, urogenital symptoms, sexuality and body image. The questionnaire also elicited written feedback from participants regarding their decision to have PBSO, what they wished they had known before surgery, advice for other BRCA carriers considering this surgery and advice for health care providers who counsel women about PBSO. Two hundred and ninety female BRCA carriers were invited to participate and 113 (39.0%) indicated they were interested. Of those, 99 (87.6%) returned their questionnaire and 98 (86.7%) responses were included in the analysis. The mean age at PBSO was 45.5 years (range: 32–63 years). The five most common “frequent” or “very frequent” post-surgical symptoms were: vaginal dryness (52.1%), changes in interest in sex (50.0%), sleep disturbances (46.7%), changes in sex life (43.9) and hot flashes (42.9%). The majority of women would have found it helpful to have more information regarding the impact of this surgery on their sex life (59.2%), the availability of sex counseling (57.1%) and the risk of coronary heart disease (57.1%). This study illustrates that while health care providers are discussing selected side effects of PBSO, women undergoing this surgery have other concerns that should be addressed. This information provides insights into the informational needs of BRCA carriers considering PBSO.

Kauff ND et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615CrossRefPubMed

Stirling D et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system. J Clin Oncol 23(24):5588–5596CrossRefPubMed

Rebbeck TR (2000) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 18(21):100S–103SPubMed

Struewing J, Hartge P, Wacholder S (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408CrossRefPubMed

Ford D, Easton D, Bishop D (1994) Risks of cancer in BRCA1 mutation carriers. Lancet 343:692–695CrossRefPubMed

Antoniou A, Pharoah P, Narod S (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analyses of 22 studies. Am J Hum Genet 72:1117CrossRefPubMed

NIH Consensus Conference (1995) Ovarian cancer: screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. JAMA 273:491–497CrossRef

Domchek S, Friebel T, Neuhausen S et al (2006) Mortality reduction after risk-reducing bilateral salpingo-oophorectomy in a prospective cohort of BRCA1 and BRCA2 mutation carriers. Lancet Oncol 7(3):223–229CrossRefPubMed

Rebbeck TR et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622CrossRefPubMed

10.

Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc 296(2):185–192CrossRef

11.

NCCN practice guidelines in oncology v.1.2009 (2010): Hereditary breast and ovarian cancer. Available via: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Cited July 26, 2010

12.

American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins—Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists (2009) ACOG practice bulletin no. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113(4):957–966

13.

Bradbury AR et al (2008) Uptake and timing of prophylactic salpingo-oophorectomy among BRCA mutation carriers. Genet Med 10(3):161–166CrossRefPubMed

14.

Meijers-Heijboer EJ et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355:2015–2020CrossRefPubMed

15.

Bachmann GA (1999) Vasomotor flushes in menopausal women. Am J Obstet Gynecol 180:S312–S316CrossRefPubMed

16.

Taylor M (2001) Psychological consequences of surgical menopause. J Reprod Med 46:317–324PubMed

17.

Madalinska JB et al (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898CrossRefPubMed

18.

Stephenson J (2003) FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 289:537–538CrossRefPubMed

19.

Madalinska JB et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24(22):3576–3582CrossRefPubMed

20.

Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds) (1975–2006) SEER cancer statistics review. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975–2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009

21.

Elit L et al (2001) Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 1:149–156CrossRefPubMed

22.

Hallowell N (2000) A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psychooncology 9:486–495CrossRefPubMed

23.

Swisher EM et al (2001) Prophylacic oophorectomy and ovarian cancer surveillance: patient perceptions and satisfaction. J Reprod Med 46:87–94PubMed

24.

Fry A et al (2001) Deciding about prophylactic oophorectomy: what is important to women at increased risk of ovarian cancer? Prev Med 33:578–585CrossRefPubMed

25.

Miller SM et al (1999) Decision making about prophylactic oophorectomy among at-risk women: psychological influences and implications. Gynecol Oncol 75:406–412CrossRefPubMed

26.

Marwick C (1999) Survey says patients expect little physician help on sex. JAMA 281(23):2173–2174CrossRefPubMed

27.

Matloff ET, Barnett RE, Bober SL (2009) Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers. Cancer J 15(1):15–18CrossRefPubMed

Title: What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salipingo-oophorectomy
Authors: Danielle Campfield Bonadies
Anne Moyer
Ellen T. Matloff
Publication date: 01-03-2011
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 1/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-010-9384-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Two BRCA1/2 founder mutations in Jews of Sephardic origin

Hereditary prostate cancer as a feature of Lynch Syndrome

An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models

Strictly defined familial male breast cancer

Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis

Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer